Bank of America’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
Other funds holding CADL
RI
ACA
PCM
SVCM
Bank of America's CADL Position: Q2 2026 in Review
Bank of America increased its Candel Therapeutics (CADL) stake by 488% in Q2 2026, buying an estimated $1.75M and bringing the position to 278,944 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #3965.
Bank of America first reported a position in CADL in Q4 2021 and has held it in 15 quarters since. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.
- Bank of America held 278,944 shares of Candel Therapeutics worth $2.87M as of Q2 2026.
- Bank of America bought 231,542 Candel Therapeutics shares in Q2 2026, an estimated $1.75M.
- Candel Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #3965 holding.
- Bank of America first reported a position in Candel Therapeutics in Q4 2021 and has held it in 15 quarters since.
- 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.